Skip to main content
  • Home
  • Prof Scott Solomon

Scott Solomon

Director, Noninvasive Cardiology / Professor

Brigham and Women's Hospital, Boston, US / Harvard Medical School


Prof Scott D Solomon is the Edward D Frohlich Distinguished Chair at Harvard Medical School, Director of Noninvasive Cardiology and Senior Physician at Brigham and Women’s Hospital. His research group has played a leading role in clinical trials in heart failure, hypertension and myocardial infarction. 

He received his AB from Williams College and his MD from Harvard Medical School. 

Featured Courses

SGLT-2 Inhibitors - Another Piece of the Puzzle in Heart Failure
  • 1 EBAC

Learning objectives

  • Recall the results of key trials in HFmrEF in different patients' sub-groups
  • Describe how SGLT-2 inhibitors can be used across the range of LVEF
  • Apply emerging diagnostic approaches for HFpEF and HFmrEF
  • Implement best-practice strategies across the range of LVEF
See more
A Review of Emerging ARNI Data in HFrEF
  • 1.00 EBAC

Learning objectives

  • Review updated data of ARNI therapy for HFrEF present at the ESC 2019;
  • understand the current utilisation of ARNI therapy in HFrEF (guidelines and databases);
  • interpret potential mechanistic data related to the clinical benefit of ARNI therapy including imaging and biomarker data;
  • apply new data covering the utilization of ARNI therapy in complex patients including recently decompensated and hospitalized; patients
  • Apply clinical and real-world evidence data for the treatment HFrEF with ARNI therapy.
See more
Current and Emerging Data on SGLT2 Inhibitors in Heart Failure
  • 1.00 EBAC

Learning objectives

  • Understand the SGLT2 inhibitor cardiovascular outcome trial (CVOT) data;
  • differentiate the latest guideline updates for the treatment of T2D and their recommendations regarding the importance of considering comorbidities, including atherosclerotic cardiovascular disease (ASCVD) and heart failure (HF);
  • apply clinical and real-world evidence of the SGLT2 inhibitor class for use in prevention of hospitalisation in HF, as well as future ongoing studies in the treatment of HF;
  • assess the interrelationships linking diabetes, HF and CVD;
  • interpret the potential cardio-renal mechanisms of the SGLT2 inhibitor class in reducing the risk of CV, including HF. Evaluate emerging data of the treatment of HF with SGLT2 inhibitors in patients with or without T2DM.
See more